Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846430 · ClinicalTrials.gov registry record · Phase 2
Medical Treatment of "High-Risk" Neurofibromas
A Phase 2 study, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00846430: Completed Phase 2 study, sponsored by Corewell Health West.
NCT00846430 is a Phase 2 study that has completed, run by Corewell Health West. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846430, a Phase 2 study, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medical therapy to offer patients with "high-risk" plexiform neurofibromas, and surgery does not provide lasting help. This study will evaluate the effectiveness of two treatment combinations in patients with "high-risk" plexiform neurofibromas.
Primary Outcome
Subjects will be evaluated for pain and Quality of Life scores
Interventions
- DRUG Celecoxib (Celebrex)
- DRUG Peg-Interferon alpha-2b
- DRUG Temozolomide (temodar)
- DRUG Vincristine Sulfate (Oncovin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-10 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
What the finished NCT00846430 record still lists
NCT00846430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Celecoxib (Celebrex) is the first listed.
NCT00846430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00846430 about?
NCT00846430 is a clinical study titled "Medical Treatment of "High-Risk" Neurofibromas". Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medic...
What is the current status of trial NCT00846430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-10. Estimated completion is 2017-05.
What interventions are being tested in trial NCT00846430?
The interventions under investigation include: Celecoxib (Celebrex) (DRUG), Peg-Interferon alpha-2b (DRUG), Temozolomide (temodar) (DRUG), Vincristine Sulfate (Oncovin) (DRUG).
Who is sponsoring clinical trial NCT00846430?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00846430's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia